Monday - Friday, 6:00 - 7:00 PM ET Merck CEO Rob Davis told CNBC's Jim Cramer that there's more to the pharmaceutical giant than its lucrative cancer drug, Keytruda, and he described other ventures in ...

Merck & Co., Inc. (NYSE:MRK) was among the stocks Jim Cramer was focused on, as he discussed Mad Money’s latest game plan for ...

Merck Chairman and CEO Robert Davis joins 'Mad Money' host Jim Cramer to talk quarterly results, what sectors it is seeing strength in, its recent acquisition of Verona Pharma and more. Got a ...

We recently compiled a list of the Jim Cramer Discussed These 12 Stocks Amidst The DeepSeek AI Selloff. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands ...

PhRMA CEO Stephen Ubl sits down with CNBC's Annika Kim Constantino to discuss PhRMA's launch of America Cures and the decision to bring in Merck CEO Rob Davis as the next Chair of the PhRMA board. Got ...

Merck CEO Rob Davis told CNBC's Jim Cramer that there's more to the pharmaceutical giant than its lucrative cancer drug, Keytruda, and he described the future of its other ventures. "Keytruda has ...

Merck Chairman and CEO Robert Davis joins 'Mad Money' host Jim Cramer at the JPMorgan Healthcare Conference to talk recent acquisitions, growth in its vaccine segment, opportunities in China and more.